当前位置： SCI文献检索 > Molecular Oncology期刊下所有文献 > Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.

Abstract：

:Molecular characterization of cancers is important in dictating prognostic factors and directing therapy. Next-generation sequencing of plasma circulating tumor DNA (ctDNA) offers less invasive, more convenient collection, and a more real-time representation of a tumor and its molecular heterogeneity than tissue. However, little is known about the clinical implications of ctDNA assessment in gynecologic cancer. We describe the molecular landscape identified on ctDNA, ctDNA concordance with tissue-based analysis, and factors associated with overall survival (OS) in gynecologic cancer patients with ctDNA analysis. We reviewed clinicopathologic and genomic information for 105 consecutive gynecologic cancer patients with ctDNA analysis, including 78 with tissue-based sequencing, enrolled in the Profile-Related Evidence Determining Individualized Cancer Therapy (NCT02478931) trial at the University of California San Diego Moores Cancer Center starting July 2014. Tumors included ovarian (47.6%), uterine (35.2%), cervical (12.4%), vulvovaginal (2.9%), and unknown gynecologic primary (1.9%). Most ovarian and uterine cancers (86%) were high grade. 34% (N = 17) of ovarian cancers had BRCA alterations, and 22% (N = 11) were platinum sensitive. Patients received median 2 (range 0-13) lines of therapy prior to ctDNA collection. Most (75.2%) had at least one characterized alteration on ctDNA analysis, and the majority had unique genomic profiles on ctDNA. Most common alterations were TP53 (N = 59, 56.2% of patients), PIK3CA (N = 26, 24.8%), KRAS (N = 14, 13.3%), BRAF (N = 10, 9.5%), ERBB2 (N = 8, 7.6%), and MYC (N = 8, 7.6%). Higher ctDNA maximum mutation allele frequency was associated with worse OS [hazard ratio (HR): 1.91, P = 0.03], while therapy matched to ctDNA alterations (N = 33 patients) was independently associated with improved OS (HR: 0.34, P = 0.007) compared to unmatched therapy (N = 28 patients) in multivariate analysis. Tissue and ctDNA genomic results showed high concordance unaffected by temporal or spatial factors. This study provides evidence for the utility of ctDNA in determining outcome and individualizing cancer therapy in patients with gynecologic cancer.

journal_name

Mol Oncol

journal_title

Molecular oncology

authors

Charo LM,Eskander RN,Okamura R,Patel SP,Nikanjam M,Lanman RB,Piccioni DE,Kato S,McHale MT,Kurzrock R

doi

10.1002/1878-0261.12791

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

67-79

issue

1

eissn

1574-7891

issn

1878-0261

journal_volume

15

pub_type

杂志文章

相关文献

Molecular Oncology文献大全
  • APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.

    abstract：:Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1 or APE1) is a multifunctional protein that regulates numerous transcription factors associated with cancer-related pathways. Because APE1 is essential for cell viability, generation of APE1-knockout cell lines and determining a comprehensive list of genes...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12138

    authors： Shah F,Goossens E,Atallah NM,Grimard M,Kelley MR,Fishel ML

    更新日期：2017-12-01 00:00:00

  • Essential role of HDAC6 in the regulation of PD-L1 in melanoma.

    abstract：:Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment. In this context, our present work demonstrates that the pharmacological or genetic abrogation of HDAC6 in primary melanoma samples ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2015.12.012

    authors： M L,P PV,T K,M P,E S,J P,K V W,C L,F C,S D,M SKS,M M,A K,J PI,A S,E S,J W,E M S,A V

    更新日期：2016-05-01 00:00:00

  • Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

    abstract：:Resistance to chemotherapy is a serious problem for the successful treatment of ovarian cancer patients but signalling pathways that contribute to this chemoinsensitivity are largely unknown. We demonstrate that the chemotherapeutic drug doxorubicin induces activation of the HER3-PI3K-AKT signalling cascade in ovarian...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2012.07.001

    authors： Bezler M,Hengstler JG,Ullrich A

    更新日期：2012-10-01 00:00:00

  • TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+ T-cell lymphoma.

    abstract：:Nucleophosmin-anaplastic lymphoma kinase-expressing (NPM-ALK+ ) T-cell lymphoma is an aggressive neoplasm that is more commonly seen in children and young adults. The pathogenesis of NPM-ALK+ T-cell lymphoma is not completely understood. Wild-type ALK is a receptor tyrosine kinase that is physiologically expressed in ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12088

    authors： Shi W,George SK,George B,Curry CV,Murzabdillaeva A,Alkan S,Amin HM

    更新日期：2017-09-01 00:00:00

  • A report from a conference jointly organised by the European Academy of Cancer Sciences and the Pontifical Academy of Sciences, The Vatican, November 16-17, 2018.

    abstract：:Cancer is a massive challenge with a significant impact on society, healthcare systems, the economy and an increasing number of patients and their families. To help meet this societal challenge, the European Commission has recently proposed a mission-oriented approach to cancer in Horizon Europe, and about 60 particip...

    journal_title：Molecular oncology

    pub_type：

    doi：10.1002/1878-0261.12436

    authors： European Academy of Cancer Sciences.

    更新日期：2019-03-01 00:00:00

  • Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

    abstract：:The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2016.03.004

    authors： Cignetto S,Modica C,Chiriaco C,Fontani L,Milla P,Michieli P,Comoglio PM,Vigna E

    更新日期：2016-06-01 00:00:00

  • miR-367 as a therapeutic target in stem-like cells from embryonal central nervous system tumors.

    abstract：:Aberrant expression of the pluripotency factor OCT4A in embryonal tumors of the central nervous system (CNS) is a key factor that contributes to tumor aggressiveness and correlates with poor patient survival. OCT4A overexpression has been shown to up-regulate miR-367, a microRNA (miRNA) that regulates pluripotency in ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12562

    authors： Kaid C,Jordan D,Bueno HMS,Araujo BHS,Assoni A,Okamoto OK

    更新日期：2019-12-01 00:00:00

  • Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).

    abstract：PURPOSE:DNA analysis by NGS has become important to direct the clinical care of cancer patients. However, NGS is not successful in all cases, and the factors responsible for test failures have not been systematically evaluated. MATERIALS AND METHODS:A series of 1528 solid and hematolymphoid tumor specimens was tested ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2015.05.004

    authors： Al-Kateb H,Nguyen TT,Steger-May K,Pfeifer JD

    更新日期：2015-11-01 00:00:00

  • Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

    abstract：:Breast cancers with BRCA1 germline mutation have a characteristic DNA copy number (CN) pattern. We developed a test that assigns CN profiles to be 'BRCA1-like' or 'non-BRCA1-like', which refers to resembling a BRCA1-mutated tumor or resembling a tumor without a BRCA1 mutation, respectively. Approximately one third of ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2015.03.002

    authors： Schouten PC,Grigoriadis A,Kuilman T,Mirza H,Watkins JA,Cooke SA,van Dyk E,Severson TM,Rueda OM,Hoogstraat M,Verhagen CV,Natrajan R,Chin SF,Lips EH,Kruizinga J,Velds A,Nieuwland M,Kerkhoven RM,Krijgsman O,Vens C,Pe

    更新日期：2015-08-01 00:00:00

  • Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1.

    abstract：:The Prep1 homeodomain transcription factor is essential for embryonic development. 25% of hypomorphic Prep1(i/i) embryos, expressing the gene at 2% of the normal levels, survive pregnancy and live a normal-length life. Later in life, however, these mice develop spontaneous pre-tumoral lesions or solid tumors (lymphoma...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2010.01.001

    authors： Longobardi E,Iotti G,Di Rosa P,Mejetta S,Bianchi F,Fernandez-Diaz LC,Micali N,Nuciforo P,Lenti E,Ponzoni M,Doglioni C,Caniatti M,Di Fiore PP,Blasi F

    更新日期：2010-04-01 00:00:00

  • EVI1 splice variants modulate functional responses in ovarian cancer cells.

    abstract：:Amplification of 3q26.2, found in many cancer lineages, is a frequent and early event in ovarian cancer. We previously defined the most frequent region of copy number increase at 3q26.2 to EVI1 (ecotropic viral integration site-1) and MDS1 (myelodysplastic syndrome 1) (aka MECOM), an observation recently confirmed by ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2013.02.008

    authors： Dutta P,Bui T,Bauckman KA,Keyomarsi K,Mills GB,Nanjundan M

    更新日期：2013-06-01 00:00:00

  • Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle.

    abstract：:Germ cell cancers (GCC) are the most frequent malignancy in young Caucasian males. GCC can consist of seminomas (SE) and non-seminomas (malignant NS: embryonal carcinoma (EC), yolk sac tumor (YS), choriocarcinoma (CH) and teratoma (TE)). Current serum-markers used for diagnosis and follow-up (AFP, hCG) are predominant...

    journal_title：Molecular oncology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.molonc.2013.08.002

    authors： Gillis AJ,Rijlaarsdam MA,Eini R,Dorssers LC,Biermann K,Murray MJ,Nicholson JC,Coleman N,Dieckmann KP,Belge G,Bullerdiek J,Xu T,Bernard N,Looijenga LH

    更新日期：2013-12-01 00:00:00

  • Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.

    abstract：:ATR-CHEK1 signalling is critical for genomic stability. ATR-CHEK1 signalling may be deregulated in breast cancer and have prognostic, predictive and therapeutic significance. We investigated ATR, CHEK1 and phosphorylated CHEK1 (Ser345) protein (pCHEK1) levels in 1712 breast cancers. ATR and CHEK1 mRNA expression was e...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.10.013

    authors： Abdel-Fatah TM,Middleton FK,Arora A,Agarwal D,Chen T,Moseley PM,Perry C,Doherty R,Chan S,Green AR,Rakha E,Ball G,Ellis IO,Curtin NJ,Madhusudan S

    更新日期：2015-03-01 00:00:00

  • Challenges in circulating tumor cell detection by the CellSearch system.

    abstract：:Enumeration and characterization of circulating tumor cells (CTC) hold the promise of a real time liquid biopsy. They are however present in a large background of hematopoietic cells making their isolation technically challenging. In 2004, the CellSearch system was introduced as the first and only FDA cleared method d...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2015.12.002

    authors： Andree KC,van Dalum G,Terstappen LW

    更新日期：2016-03-01 00:00:00

  • Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cδ activation in pancreatic ductal adenocarcinoma.

    abstract：:Pancreatic cancer is one of the most lethal human cancers, and radiotherapy is often implemented for locally advanced pancreatic ductal adenocarcinoma. Tumor cell repopulation is a major challenge in treating cancers after radiotherapy. In order to address the problem of tumor repopulation, our previous studies have d...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.07.024

    authors： Cheng J,Tian L,Ma J,Gong Y,Zhang Z,Chen Z,Xu B,Xiong H,Li C,Huang Q

    更新日期：2015-01-01 00:00:00

  • Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: an evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice.

    abstract：:Targeted toxin-based therapeutics are hindered by poor intracellular uptake, limited stability and non-specific immune stimulation. To address these problems, ligand-targeted toxins in combination with low dose saponin mixtures have been adapted and tested in vivo in the past, however, undefined saponin raw mixtures a...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2012.12.004

    authors： Thakur M,Mergel K,Weng A,von Mallinckrodt B,Gilabert-Oriol R,Dürkop H,Melzig MF,Fuchs H

    更新日期：2013-06-01 00:00:00

  • p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.

    abstract：:Tumour suppressor p53, a master transcriptional regulator determines cell fate through preferential activation/repression of a myriad of genes during stress. Till date, activation and preferential binding of p53 on different promoters was reported to be influenced by the nature, strength and duration of stress which m...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2016.06.006

    authors： Thakur B,Ray P

    更新日期：2016-10-01 00:00:00

  • Cell-to-cell communication: microRNAs as hormones.

    abstract：:Mammalian cells can release different types of extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies. Accumulating evidence suggests that EVs play a role in cell-to-cell communication within the tumor microenvironment. EVs' components, such as proteins, noncoding RNAs [microRNAs (miRNAs...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1002/1878-0261.12144

    authors： Bayraktar R,Van Roosbroeck K,Calin GA

    更新日期：2017-12-01 00:00:00

  • Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.

    abstract：BACKGROUND:DNA methylation alterations are early events in tumorigenesis and important in the regulation of gene expression in cancer cells. Lung cancer patients have in general a poor prognosis, and a deeper insight into the epigenetic landscape in lung adenocarcinoma tumors and its prognostic implications is needed. ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2015.10.021

    authors： Bjaanæs MM,Fleischer T,Halvorsen AR,Daunay A,Busato F,Solberg S,Jørgensen L,Kure E,Edvardsen H,Børresen-Dale AL,Brustugun OT,Tost J,Kristensen V,Helland Å

    更新日期：2016-02-01 00:00:00

  • Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.

    abstract：:Thyroid transcription factor-1 (TTF-1, encoded by the NKX2-1 gene) is highly expressed in small-cell lung carcinoma (SCLC) and lung adenocarcinoma (LADC), but how its functional roles differ between SCLC and LADC remains to be elucidated. Here, we compared the genome-wide distributions of TTF-1 binding regions and the...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12608

    authors： Hokari S,Tamura Y,Kaneda A,Katsura A,Morikawa M,Murai F,Ehata S,Tsutsumi S,Ishikawa Y,Aburatani H,Kikuchi T,Miyazono K,Koinuma D

    更新日期：2020-02-01 00:00:00

  • Genotoxic stress induces Sca-1-expressing metastatic mammary cancer cells.

    abstract：:We describe a cell damage-induced phenotype in mammary carcinoma cells involving acquisition of enhanced migratory and metastatic properties. Induction of this state by radiation required increased activity of the Ptgs2 gene product cyclooxygenase 2 (Cox2), secretion of its bioactive lipid product prostaglandin E2 (PG...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12321

    authors： Gong J,Lang BJ,Weng D,Eguchi T,Murshid A,Borges TJ,Doshi S,Song B,Stevenson MA,Calderwood SK

    更新日期：2018-08-01 00:00:00

  • MicroRNA let-7b regulates genomic balance by targeting Aurora B kinase.

    abstract：:The let-7 microRNA (miRNA) family has been implicated in the regulation of diverse cellular processes and disease pathogenesis. In cancer, loss-of-function of let-7 miRNAs has been linked to tumorigenesis via increased expression of target oncogenes. Excessive proliferation rate of tumor cells is often associated with...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2015.01.005

    authors： Mäki-Jouppila JH,Pruikkonen S,Tambe MB,Aure MR,Halonen T,Salmela AL,Laine L,Børresen-Dale AL,Kallio MJ

    更新日期：2015-06-01 00:00:00

  • Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.

    abstract：:Targeted therapy for patients with HER2-positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failure, but little work...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12375

    authors： Rye IH,Trinh A,Saetersdal AB,Nebdal D,Lingjaerde OC,Almendro V,Polyak K,Børresen-Dale AL,Helland Å,Markowetz F,Russnes HG

    更新日期：2018-11-01 00:00:00

  • Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.

    abstract：:Standard treatments for advanced high-grade serous ovarian carcinomas (HGSOCs) show significant side-effects and provide only short-term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin-embedded HGSOCs, to evalu...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.09.010

    authors： Kamieniak MM,Rico D,Milne RL,Muñoz-Repeto I,Ibáñez K,Grillo MA,Domingo S,Borrego S,Cazorla A,García-Bueno JM,Hernando S,García-Donas J,Hernández-Agudo E,Y Cajal TR,Robles-Díaz L,Márquez-Rodas I,Cusidó M,Sáez R,Lacambr

    更新日期：2015-02-01 00:00:00

  • Genetic susceptibility to breast cancer.

    abstract：:Genetic and lifestyle/environmental factors are implicated in the aetiology of breast cancer. This review summarizes the current state of knowledge on rare high penetrance mutations, as well as moderate and low-penetrance genetic variants implicated in breast cancer aetiology. We summarize recent discoveries from larg...

    journal_title：Molecular oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.molonc.2010.04.011

    authors： Mavaddat N,Antoniou AC,Easton DF,Garcia-Closas M

    更新日期：2010-06-01 00:00:00

  • Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.

    abstract：:Alterations in glycan structures are early signs of malignancy and have recently been proposed to be in part a driving force behind malignant transformation. Here, we explore whether differences in expression of genes related to the process of glycosylation exist between breast carcinoma subtypes - and look for their ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2014.12.013

    authors： Potapenko IO,Lüders T,Russnes HG,Helland Å,Sørlie T,Kristensen VN,Nord S,Lingjærde OC,Børresen-Dale AL,Haakensen VD

    更新日期：2015-04-01 00:00:00

  • Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

    abstract：:Our limited understanding of the biological impact of the whole spectrum of early breast lesions together with a lack of accurate molecular-based risk criteria for the diagnosis and assignment of prognostic significance to biopsy findings presents an important problem in the clinical management of patients harboring p...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1016/j.molonc.2010.09.005

    authors： Moreira JM,Cabezón T,Gromova I,Gromov P,Timmermans-Wielenga V,Machado I,Llombart-Bosch A,Kroman N,Rank F,Celis JE

    更新日期：2010-12-01 00:00:00

  • Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse.

    abstract：:Patient derived xenografts (PDXs) are increasingly appreciated models in cancer research, particularly for preclinical testing, as they reflect the patient's tumor biology more accurately than cancer cell lines. We have established a collection of 20 breast PDXs and characterized their biological and clinical features...

    journal_title：Molecular oncology

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.molonc.2013.11.010

    authors： du Manoir S,Orsetti B,Bras-Gonçalves R,Nguyen TT,Lasorsa L,Boissière F,Massemin B,Colombo PE,Bibeau F,Jacot W,Theillet C

    更新日期：2014-03-01 00:00:00

  • The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma.

    abstract：:Ewing sarcomas (ES) are highly malignant, osteolytic bone or soft tissue tumors, which are characterized by EWS-ETS translocations and early metastasis to lung and bone. In this study, we investigated the role of the BRICHOS chaperone domain-containing endochondral bone protein chondromodulin I (CHM1) in ES pathogenes...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12057

    authors： von Heyking K,Calzada-Wack J,Göllner S,Neff F,Schmidt O,Hensel T,Schirmer D,Fasan A,Esposito I,Müller-Tidow C,Sorensen PH,Burdach S,Richter GHS

    更新日期：2017-09-01 00:00:00

  • Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.

    abstract：:Ovarian cancer is the most lethal gynecologic malignancy. About 75% of ovarian cancer patients relapse and/or develop chemo-resistant disease after initial response to standard-of-care treatment with platinum-based therapies. HER2 amplifications and overexpression in ovarian cancer are reported to vary, and responses ...

    journal_title：Molecular oncology

    pub_type： 杂志文章

    doi：10.1002/1878-0261.12414

    authors： Harris FR,Zhang P,Yang L,Hou X,Leventakos K,Weroha SJ,Vasmatzis G,Kovtun IV

    更新日期：2019-02-01 00:00:00